Quantitative imaging of schwannoma captures heterogeneity and accelerates preclinical testing, exposing distinct therapeutic signatures

Read full text Summarise with VIRAT
Authors: Emily Wright, Jérémie Vitte, Sara I. Veiga, Sarah Bushnell, Catherin Movsessian, Youwen Zhang, Jacquelyn M. Curtis, Ryan Bruce Corcoran, Shannon L. Stott, Marco Giovannini, Christine Chiasson-MacKenzie, Andrea I. McClatchey
Cited by: 0
References: 57

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Schwannomas are debilitating hallmarks of familial schwannomatoses and common sporadic tumors that form on spinal and cranial nerves. Drug-based therapies for schwannoma are desperately needed but their development has been extremely slow and disappointing, impeded particularly by the poorly understood and surprisingly complex and heterogeneous biology of schwannomas, and by the inefficient use of physiologically relevant in vivo preclinical models. We have addressed these gaps by developing a quantitative imaging-centered workflow that allows both a deep analysis of schwannoma development and accelerated preclinical testing in a widely used genetically engineered mouse model of neurofibromatosis type 2-related schwannomatosis ( NF2 -SWN). We deployed our workflow to study schwannoma development and to test three clinically relevant drugs head-to-head. Our results uncovered the very early onset of heterogeneity and macrophage recruitment to initiating schwannomas and unexpectedly revealed that although all three drugs inhibited proliferation within the developing schwannomas, they did so while triggering one of two distinct response signatures, highlighting the value of our pipeline for both rapid drug-testing and translational discovery. Significance Statement Schwannomas are common sporadic tumors that grow on cranial and spinal nerves, as well as defining features of familial schwannomatosis. Therapeutic advance has been hampered by the striking heterogeneity of schwannomas, Schwann cell plasticity, and the poorly understood biology of interactions between tumor cells and the microenvironment. To address this gap, we exploited a widely used mouse model of schwannomatosis to develop a quantitative imaging platform that captures diverse tumor features, including proliferation, biomarkers of heterogeneity, and macrophage recruitment. We deployed this workflow to holistically compare three clinically active drugs head-to-head and discovered that despite similarly inhibiting proliferation, the drugs induced two distinct response signatures, underscoring the value of this pipeline for accelerated preclinical testing and discovery-based studies.

Fields of Study & Subjects

Neurofibromatosis and Schwannoma Cases Glioma Diagnosis and Treatment Neuroblastoma Research and Treatments

Publication details

Journal / source
bioRxiv (Cold Spring Harbor Laboratory)
Publication date
26 March 2026
Language
EN
Document type
Preprint